Online citations, reference lists, and bibliographies.

Metabolic Tumor Volume Predicts For Recurrence And Death In Head-and-neck Cancer.

Trang H. La, Edith J. Filion, Brit B. Turnbull, Jackie Chu, Percy P. Lee, Khoa Thanh Nguyen, Peter G. Maxim, Andy Quon, Edward E Graves, Billy W. Loo, Quynh-Thu Le
Published 2009 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
PURPOSE To evaluate the prognostic value of metabolic tumor volume measured on 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) imaging and other clinical factors in patients treated for locally advanced head-and-neck cancer (HNC) at a single institution. MATERIALS AND METHODS Between March 2003 and August 2007, 85 patients received positron emission tomography (PET)/computed tomography-guided chemoradiotherapy for HNC. Metabolically active tumor regions were delineated on pretreatment PET scans semiautomatically using custom software. We evaluated the relationship of (18)F-fluorodeoxyglucose-PET maximum standardized uptake value (SUV) and total metabolic tumor volume (MTV) with disease-free survival (DFS) and overall survival (OS). RESULTS Mean follow-up for surviving patients was 20.4 months. The estimated 2-year locoregional control, DFS, and OS for the group were 88.0%, 69.5%, and 78.4%, respectively. The median time to first failure was 9.8 months among the 16 patients with relapse. An increase in MTV of 17.4 mL (difference between the 75th and 25th percentiles) was significantly associated with an increased hazard of first event (recurrence or death) (1.9-fold, p < 0.001), even after controlling for Karnofsky performance status (KPS) (1.8-fold, p = 0.001), and of death (2.1-fold, p < 0.001). We did not find a significant relationship of maximum SUV, stage, or other clinical factors with DFS or OS. CONCLUSIONS Metabolic tumor volume is an adverse prognostic factor for disease recurrence and death in HNC. MTV retained significance after controlling for KPS, the only other significant adverse prognostic factor found in this cohort. MTV is a direct measure of tumor burden and is a potentially valuable tool for risk stratification and guiding treatment in future studies.



This paper is referenced by
10.1016/j.ijrobp.2011.05.061
Quantitation of human papillomavirus DNA in plasma of oropharyngeal carcinoma patients.
Hongbin Cao (2012)
10.1016/j.lungcan.2012.08.016
Metabolic imaging metrics correlate with survival in early stage lung cancer treated with stereotactic ablative radiotherapy.
Jonathan A Abelson (2012)
10.1097/MNM.0000000000000267
Potential values of metabolic tumor volume and heterogeneity measured with 18F-FDG PET/CT pretreatment to evaluate local control for esophageal squamous cell carcinoma treated with nonsurgical therapy
Qi Liu (2015)
10.1111/1754-9485.12439
18F-FDG PET-CT performed before and during radiation therapy of head and neck squamous cell carcinoma: Are they independent or complementary to each other?
Myo Min (2016)
10.3413/Nukmed-0367-10-11
Metabolic tumour volume. Prognostic value in locally advanced squamous cell carcinoma of the head and neck.
Philippe Deron (2011)
10.1371/journal.pone.0072230
Dynamic Contrast-Enhanced MR Imaging Predicts Local Control in Oropharyngeal or Hypopharyngeal Squamous Cell Carcinoma Treated with Chemoradiotherapy
Shu-Hang Ng (2013)
10.1002/hed.24048
Prognostic evaluation of percentage variation of metabolic tumor burden calculated by dual-phase (18) FDG PET-CT imaging in patients with head and neck cancer.
Ronan Abgral (2016)
18 F-FDG PET / CT Metabolic Tumor Volume and Total Lesion Glycolysis Predict Outcome in Oropharyngeal Squamous Cell Carcinoma
Remy Lim (2012)
Clinical Assessment of Lung Cancer Using 18F-FDG PET-CT
Seyyed Hossein Hassanpour (2018)
10.1111/1471-0528.12543
Metabolic tumour volume and total lesion glycolysis, measured using preoperative 18F-FDG PET/CT, predict the recurrence of endometrial cancer.
S-h Shim (2014)
10.1186/s40463-014-0033-7
Metabolic tumour volume as a prognostic factor for oral cavity squamous cell carcinoma treated with primary surgery
Han Zhang (2014)
10.1007/s00259-014-2933-1
Zone-size nonuniformity of 18F-FDG PET regional textural features predicts survival in patients with oropharyngeal cancer
Nai-Ming Cheng (2014)
10.1007/978-3-319-26067-9_10-1
Diagnostic Applications of Nuclear Medicine: Head and Neck Cancer
Heiko Schöder (2016)
10.1007/s13566-012-0065-4
Prognostic value of 18F-FDG PET metabolic parameters in oropharyngeal squamous cell carcinoma
Adam A. Garsa (2012)
10.1148/radiol.12111148
Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer.
Helen H. W. Chen (2012)
10.1016/j.oraloncology.2016.03.013
Validation of metabolic tumor volume as a prognostic factor for oral cavity squamous cell carcinoma treated with primary surgery.
Han Zhang (2016)
10.1007/s11604-017-0686-z
Prognostic value of volumetric FDG PET/CT parameters in patients with oral tongue squamous cell carcinoma who were treated by superselective intra-arterial chemoradiotherapy
Satoko Suzuki-Shibata (2017)
10.1002/hed.22904
Prognostic value of 18F-FDG PET/CT in patients with squamous cell carcinoma of the tonsil: comparisons of volume-based metabolic parameters.
Seung Hwan Moon (2013)
10.1007/s00432-010-0972-y
18F-FDG PET or PET-CT to evaluate prognosis for head and neck cancer: a meta-analysis
Peng Xie (2010)
10.1016/j.critrevonc.2016.10.009
Overview of the predictive value of quantitative 18 FDG PET in head and neck cancer treated with chemoradiotherapy.
Joël Castelli (2016)
10.1111/crj.12391
Total lesion glycolysis by 18F‐FDG PET/CT is independent prognostic factor in patients with advanced non‐small cell lung cancer
Fatma Yıldırım (2017)
10.1002/hed.24454
Prognostic value of midtreatment FDG-PET in oropharyngeal cancer.
Erqi L Pollom (2016)
Localising Anatomical Structures and Quantifying Tumour Burden in PET/CT Images using Machine Learning
Marie Bieth (2017)
10.1097/PPO.0b013e31821e8a09
Head and Neck Cancer as a Model for Advances in Imaging Prognosis, Early Assessment, and Posttherapy Evaluation
David M. Brizel (2011)
Lesion Glycolysis Predict Outcome in Oropharyngeal Squamous Cell Carcinoma
Remy Lim (2012)
10.1186/1748-717X-8-174
Oropharyngeal squamous cell carcinoma with known human papillomavirus status treated with definitive chemoradiotherapy: patterns of failure and toxicity outcomes
Trevor J Bledsoe (2013)
10.1148/radiol.13130652
Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value.
Yoko Satoh (2014)
10.1097/RLU.0000000000000652
Prognostic Value Comparison Between 18F-FLT PET/CT and 18F-FDG PET/CT Volume-Based Metabolic Parameters in Patients with Head and Neck Cancer
Hiroshi Hoshikawa (2015)
10.2214/AJR.14.13906
Whole-Body Metabolic Tumor Volume, as Determined by (18)F-FDG PET/CT, as a Prognostic Factor of Outcome for Patients With Breast Cancer Who Have Distant Metastasis.
Seung Ha Son (2015)
10.1016/j.canrad.2017.10.003
(18F)-FDG PET/CT parameters to predict survival and recurrence in patients with locally advanced cervical cancer treated with chemoradiotherapy.
Nathaniel Scher (2018)
10.1016/j.ijrobp.2010.11.050
Analysis of pretreatment FDG-PET SUV parameters in head-and-neck cancer: tumor SUVmean has superior prognostic value.
Kristin Higgins (2012)
10.3348/kjr.2012.13.6.752
Prognostic Value of Volume-Based 18F-Fluorodeoxyglucose PET/CT Parameters in Patients with Clinically Node-Negative Oral Tongue Squamous Cell Carcinoma
Su Jin Lee (2012)
See more
Semantic Scholar Logo Some data provided by SemanticScholar